Heart Disease
New data from France, Netherlands and the United States lluminates research in heart disease
Published in Hematology Week, July 10th, 2006
Study 1: Angiotensin-converting enzyme inhibitors reduce total mortality and major cardiovascular end points in coronary artery disease patients without heart failure or left ventricular systolic dysfunction.
"Results of randomized trials of angiotensin-converting enzyme inhibitors in patients with coronary artery disease (CAD) and preserved left ventricular function are conflicting. We undertook this study to determine whether long-term prescription of angiotensin-converting enzyme inhibitors decreases major cardiovascular events and mortality in patients...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2006-07-10)
More Articles from Hematology Week
- Ischemia
White cells play key role in renal ischemia-reperfusion injury - Stem Cell Research
Moz protein is essential for the development of long-term reconstituting hematopoietic stem cells - Stem Cell Transplantation
Donor-derived hematologic malignancies occurred after stem cell transplantation - Acute Myeloid Leukemia
Acute myeloid leukemia managed on outpatient basis - Allergy & Immunology
Platelets target dendritic cell differentiation and production of proinflammatory cytokines - Angiology
CABG patency may be assessed with a magnetic resonance spin echo sequence - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
